Biogen (BIIB) Q4 FY24 earnings call

Biogen's Q4 FY24 results show a strategic pivot with new product launches, including LEQEMBI and SKYCLARYS, successfully offsetting the decline in the multiple sclerosis franchise. The company is focused on pipeline reprioritization and operational efficiency through its Fit for Growth initiative, aiming to build a new phase of growth. Management highlighted the pioneering nature and commercial challenges of its first-in-class therapies, while also emphasizing significant free cash flow generation and a strong balance sheet for future investment.